Created on Thursday, 12 Sep 2019. Posted in Priorities
Citing the James Lind Alliance Priority Setting (JLA PS) as a reason why the research is important is a good way to justify your research question, however you need to do more that just say that JLA identified it as a priority!
In one or two sentences explain how the JLA PS resulted in the research question being posed. Provide numbers of people involved in the process of setting the priority, where it ranked and what the reasons were for setting it as a priority. Most importantly remember to say what difference answering that uncertainty will make to the NHS and patients.
This scoping review describes the extent and nature of PPI in dementia research in the European Union (EU) and summarises: (i) how PPI is carried out; and (ii) the impact of PPI on people living with dementia and the public, researchers, and the research process.
Created on Tuesday, 10 Sep 2019.
Fast track the impact of your research with evidence-based tools you can use immediately. Second edition is ully updated and redesigned with over 100 pages of new material, packed full of practical tips, techniques, templates, case studies and personal stories that will inspire and equip you with the skills and confidence you need to make a difference.
NHS Health Research Authority have launched new guidelines on how to involve patients and the public well in research.
The new webpages introduce four key principles for best practice in public involvement:
Created on Friday, 05 Jul 2019. Posted in Toolkit/Database
The NIHR has launched a new toolkit for researchers, to help them deliver the high quality health services research that the NHS needs.
The Health Services Research Toolkit is a national resource which brings together ideas, guidance and support in one place.
Created on Friday, 05 Jul 2019. Posted in News Items
Be Part of Research website aims to make it easier for the public to take part in UK research. (The UK Clinical Trials Gateway has now been replaced with Be Part of Research)
Created on Wednesday, 03 Jul 2019. Posted in Funding
HTA has decided to no longer fund feasibility projects in its researcher led workstream. This is due to the fact that they are often costed at 4 times the equivalent of a feasibility project going to RfPB, they're over engineered and its difficult to judge value for money as the size and effect of a main trial remain obscure.
Instead HTA would like to see full trials with robust internal pilots to evaluate key feasibility outcomes and will fund such projects through staged payments.
HTA will continue to fund feasibility studies though it's commissioned workstream where the work is deemed to be absolutely essential and isn't likely to be funded selsewhere.
Lastly if a clinical trial is submitted to HTA based on a feasibility study you need to ensure that along side feasibility there also needs to be a convincing efficacy signal otherwise its unlikely to be funded.
Created on Monday, 24 Jun 2019. Posted in Co-production
An update from Gary Hickey, NIHR INVOLVE: Our work on co-production continues to gain traction. We recently co-hosted, along with colleagues from the Centre for Public Engagement, Kingston University and St George’s, University of London and University College London Centre for Co-production in Health Research a successful event on ‘Co-producing Research: How do we share power?’ Next up is a Research Medical Society and BMJ co-sponsored event ‘Research co-production: What it is and how to do it’. This will be followed by a presentation at the Social Care Institute for Excellence event on ‘Sharing Power’ as part of National Co-production Week. Our work is also being referenced in publications on co-production, for example a recently released Carnegie Trust UK piece of work ‘The many shades of co-produced evidence’. Finally, please look out for an upcoming publication ‘Co-production in Action’. This will be the first in a series of three publications providing examples of co-produced research in practice.
Created on Wednesday, 29 May 2019. Posted in RDS EM Newsletter
RDS EM newsletter with an editorial on the minimum clinically important difference - effect size. Associate Professor Damian Rolands shares to story of his journey from an NIHR fellowhip to gaining RfPB funding as a new investigator and our Noticeboard is full of toolkits, databases and templates to help you with your applications.